BioPharmX (BPMX) Misses Q4 EPS by 1c

BioPharmX (NYSE: BPMX) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $35 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on BioPharmX (BPMX) click here.

You May Also Be Interested In

• Verizon to cut 3,000 jobs as it shifts stores to franchises
• F.N.B. Corp (FNB) Reports In-Line Q2 EPS
• Regions Financial (RF) Tops Q2 EPS by 5c